Immatics

📍 Tuebingen, Germany🗓 Founded 2000👥 426 employees💰 Last funded May 2009
Biotechnology Research🌐 immatics.com
Website LinkedIn
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Twitter: https://twitter.com/immatics Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
3
Total investors
0
Early stage
2
Mid stage
1
Late stage
2000
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Germany
2
Switzerland
1
Investor activity2004–2009 · investors recorded per year
2004220091
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Immatics?
Immatics has 3 investors on record on gritt.io, 2 mid-stage and 1 late-stage investors.
When did Immatics last raise funding?
The most recent investment in Immatics recorded on gritt.io was in May 2009.
When was Immatics founded?
Immatics was founded in 2000.
What industry is Immatics in?
Immatics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Immatics based?
Immatics is headquartered in Tuebingen, Germany.